Table 3. Association between baseline cardiovascular profile and adjuvant treatment administration in 1,876 women with non-metastatic breast cancer.

Cardiovascular profile at initial cancer diagnosis	Adjuvant therapy administration
	OR for chemotherapy (95% CI)a	OR for radiotherapy (95% CI)b	OR for endocrine therapy (95% CI)c	OR for trastuzumab (95% CI)d
Pre-existing CVDe
Yes	0.32 (0.17–0.58)	0.63 (0.37–1.08)	0.47 (0.21–1.09)	-
No	1.00	1.00	1.00	-
Presence of two or more modifiable risk factors of CVDf
Yes	0.95 (0.71–1.28)	1.12 (0.86–1.44)	1.60 (1.10–2.50)	0.67 (0.39–1.15)
No	1.00	1.00	1.00	1.00
Family history of early-onset coronary heart diseaseg
Yes	0.89 (0.59–1.36)	1.22 (0.83–1.78)	1.02 (0.55–1.88)	1.31 (0.69–2.82)
No	1.00	1.00	1.00	1.00

^aThis analysis included 1,752 women of whom 1,105 received adjuvant chemotherapy (124 patients with unknown chemotherapy status were excluded). Results were derived using a multivariable logistic regression model including preexisting CVD, presence of ≥2 risk factors of CVD and family history of early-onset coronary heart disease, adjusted for age (years), ethnicity (Chinese, Malay, Indian, others), type of hospital (public, private, university), tumour size category (pT1, pT2, pT3, pT4), lymph node status (pN0, pN1, pN2, pN3), oestrogen/progesterone receptor status (positive, negative), human epidermal growth factor receptor 2 status (positive, negative), tumour grade (I, II, III), adjuvant radiotherapy administration (no, yes), adjuvant endocrine therapy administration (no, yes) and trastuzumab administration (no, yes)

^bThis analysis included 1,749 women of whom 1,104 received adjuvant radiotherapy (127 patients with unknown radiotherapy status were excluded). Results were derived using a model similar as in (a) but mutually adjusted for adjuvant chemotherapy status, adjuvant endocrine therapy status and trastuzumab administration

^cThis analysis included 1,790 women of whom 1,115 received adjuvant endocrine therapy (86 patients with unknown endocrine therapy status were excluded). Results were derived using a model similar as in (a) but mutually adjusted for adjuvant chemotherapy status, adjuvant radiotherapy status and trastuzumab administration

^dThis analysis included 1,834 women of whom 126 received trastuzumab (42 patients with unknown trastuzumab administration status were excluded). Results were derived using a multivariable logistic regression model including presence of ≥2 risk factors of CVD and family history of early-onset coronary heart disease, adjusted for age, type of hospital, human epidermal growth factor receptor 2 status, adjuvant chemotherapy status, adjuvant radiotherapy administration and adjuvant endocrine therapy status

^eComprises angina, myocardial infarction, stroke, atrial fibrillation, valvular diseases, heart failure, cardiomyopathy and rheumatic heart disease

^fIncludes hypertension, diabetes mellitus, obesity, dyslipidaemia and smoking

^gDefined as coronary heart disease diagnosed before the age of 60 years in a first-degree relative